NEW YORK (GenomeWeb) – Vermillion said today that it has entered into a share repurchase agreement with Quest Diagnostics.

Under the agreement, Vermillion on June 17, 2015 purchased from Quest 860,595 shares of its common stock for a total of around $1.3 million, or $1.50 per share.

The share price was based on a simple average of closing prices per share of Vermillion's common stock for a trailing 60-day period and was then reduced by an amount negotiated by the two parties.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.